AGT and Hypertension: In summary, these results suggest that VEGFCc156s treatment improved angiotensin II-induced kidney dysfunction and ameliorated the response of renal lymphatics to systemic hypertension, supporting the observation that VEGFCc156s ameliorated angiotensin II infusion-induced hypertension.